Key result
Cardiac contractility modulation, carotid baroreceptor, and phrenic nerve stimulation emerge as therapies for advanced HF.
Why the study?
Most symptomatic HF patients are poor candidates for CRT, leaving a need to examine newly approved evolving electrical therapies for advanced HF.
Emerging FDA-approved electrical therapies provide new therapeutic options for symptomatic heart failure patients who are poor candidates for cardiac resynchronization therapy.
Answers are grounded in this paper and cite their sources.
May expand options for CRT-ineligible advanced HF; leaves open need for confirmatory RCTs before practice change.
Symptomatic heart failure (HF) patients despite optimal medical therapy and advances such as invasive hemodynamic monitoring remain challenging to manage. While cardiac resynchronization therapy remains a highly effective therapy for a subset of HF patients with wide QRS, a majority of symptomatic HF patients are poor candidates for such. Recently, cardiac contractility modulation, neuromodulation based on carotid baroreceptor stimulation, and phrenic nerve stimulation have been approved by the US Food and Drug Administration and are emerging as therapeutic options for symptomatic HF patients. This state-of-the-art review examines the role of these evolving electrical therapies in advanced HF.
No takes yet. Share an insight, caveat, or question.
Sharif et al. (2021) conducted a review in Advanced Heart Failure. Cardiac electrical therapies was evaluated. Cardiac contractility modulation, carotid baroreceptor stimulation, and phrenic nerve stimulation are emerging as therapeutic options for symptomatic advanced heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: